FDA finds 'final link' in heparin case
For the first time, the FDA has conclusively tied patients' deaths to the contaminant found in Baxter's heparin blood thinner. Of 10 deaths reported from anaphylactic shock, three of them were traced to lot numbers of the drug that tested positive for oversulfated chondroitin sulfate. (The lot numbers of the other seven weren't known.) "We have what looks like cause and effect in some patients," Dr. Janet Woodcock, CDER chief, told the Chicago Tribune. "This is one of the final links in the chain."
As you know, Baxter recalled its heparin products in February after a spike in severe allergic reactions to the drug. The investigation led to suppliers in China, which, some officials said, may have contaminated raw heparin deliberately to save money. In the process, the probe raised questions about just how close an eye drugmakers keep on their foreign supply chains; Baxter admitted that it didn't know much about the ultimate source of the ingredient it bought from Scientific Protein Laboratories, which operated a plant in China. All told, FDA counted more than reports of more than 90 deaths and 1,000 adverse reactions to heparin.
- read the story in the Tribune
Related Articles:
Heparin mimic found in suspect samples
Heparin suspected in more deaths
Heparin supply chain full of loopholes
Baxter stops making multidose heparin
Comments
Post new comment
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
- Forecast Model: Antidyslipidemics - Genericization and negative trial data drive market shrinkage


